[go: up one dir, main page]

WO2006130607A3 - Controlled-release formulation useful for treating disorders associated with hepatitis c virus - Google Patents

Controlled-release formulation useful for treating disorders associated with hepatitis c virus Download PDF

Info

Publication number
WO2006130607A3
WO2006130607A3 PCT/US2006/020969 US2006020969W WO2006130607A3 WO 2006130607 A3 WO2006130607 A3 WO 2006130607A3 US 2006020969 W US2006020969 W US 2006020969W WO 2006130607 A3 WO2006130607 A3 WO 2006130607A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled
hepatitis
virus
release formulation
disorders associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/020969
Other languages
French (fr)
Other versions
WO2006130607A2 (en
Inventor
Bruce A Malcolm
Prudence K Bradley
Wing-Kee Philip Cho
Zhihui Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to NZ563369A priority Critical patent/NZ563369A/en
Priority to AU2006252623A priority patent/AU2006252623A1/en
Priority to EP06760559A priority patent/EP1898941A2/en
Priority to JP2008514780A priority patent/JP2008545748A/en
Priority to CA002611145A priority patent/CA2611145A1/en
Publication of WO2006130607A2 publication Critical patent/WO2006130607A2/en
Publication of WO2006130607A3 publication Critical patent/WO2006130607A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Controlled release dosage formulations including at least one compound of Formulae (I) to (XXVI) herein and a controlled-release carrier and methods of treatment using the same as provided.
PCT/US2006/020969 2005-06-02 2006-05-31 Controlled-release formulation useful for treating disorders associated with hepatitis c virus Ceased WO2006130607A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
NZ563369A NZ563369A (en) 2005-06-02 2006-05-31 Controlled-release formulation useful for treating disorders associated with hepatitus C virus
AU2006252623A AU2006252623A1 (en) 2005-06-02 2006-05-31 Controlled-release formulation useful for treating disorders associated with hepatitis C virus
EP06760559A EP1898941A2 (en) 2005-06-02 2006-05-31 Controlled-release formulation useful for treating disorders associated with hepatitis c virus
JP2008514780A JP2008545748A (en) 2005-06-02 2006-05-31 Sustained release formulations useful for treating disorders associated with hepatitis C virus
CA002611145A CA2611145A1 (en) 2005-06-02 2006-05-31 Controlled-release formulation useful for treating disorders associated with hepatitis c virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68686105P 2005-06-02 2005-06-02
US60/686,861 2005-06-02

Publications (2)

Publication Number Publication Date
WO2006130607A2 WO2006130607A2 (en) 2006-12-07
WO2006130607A3 true WO2006130607A3 (en) 2007-09-13

Family

ID=37482224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/020969 Ceased WO2006130607A2 (en) 2005-06-02 2006-05-31 Controlled-release formulation useful for treating disorders associated with hepatitis c virus

Country Status (6)

Country Link
EP (1) EP1898941A2 (en)
JP (1) JP2008545748A (en)
AU (1) AU2006252623A1 (en)
CA (1) CA2611145A1 (en)
NZ (1) NZ563369A (en)
WO (1) WO2006130607A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9163061B2 (en) 2007-12-21 2015-10-20 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009055335A2 (en) * 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
TWI487522B (en) 2007-12-21 2015-06-11 賽基艾維洛米斯研究股份有限公司 Hcv protease inhibitors and uses thereof
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5529120B2 (en) 2008-05-29 2014-06-25 ブリストル−マイヤーズ スクイブ カンパニー Hepatitis C virus inhibitor
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2011530532A (en) * 2008-08-07 2011-12-22 シェーリング コーポレイション Pharmaceutical formulations of HCV protease inhibitors in solid molecular dispersions
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
PL2477980T3 (en) 2009-09-15 2017-02-28 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
EP2658858A4 (en) 2010-12-30 2014-06-25 Enanta Pharm Inc Phenanthridine macrocyclic hepatitis c serine protease inhibitors
MX2013007677A (en) 2010-12-30 2013-07-30 Abbvie Inc Macrocyclic hepatitis c serine protease inhibitors.
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX360452B (en) 2012-10-19 2018-11-01 Bristol Myers Squibb Co Hepatitis c virus inhibitors.
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (en) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Hepatitis C virus inhibitor
CN103387510B (en) * 2013-08-08 2015-09-09 苏州永健生物医药有限公司 A kind of synthetic method of β-amino-alpha-hydroxycyclobutylbutanamide hydrochloride
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008244A2 (en) * 2000-07-21 2002-01-31 Schering Corporation Peptides as ns3-serine protease inhibitors of hepatitis c virus
WO2003062228A1 (en) * 2002-01-23 2003-07-31 Schering Corporation Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
WO2003062265A2 (en) * 2002-01-18 2003-07-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
US20050020689A1 (en) * 2003-06-17 2005-01-27 Schering Corporation Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof
US20050059648A1 (en) * 2003-06-17 2005-03-17 Schering Corporation Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof
US20050085425A1 (en) * 2003-08-26 2005-04-21 Schering Corporation Novel peptidomimetic NS3-serine protease inhibitors of hepatitis C virus
WO2005085275A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis c virus ns3 protease
WO2005085242A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
WO2005085197A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005087725A2 (en) * 2004-02-27 2005-09-22 Schering Corporation Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005087721A2 (en) * 2004-02-27 2005-09-22 Schering Corporation Compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005087731A1 (en) * 2004-02-27 2005-09-22 Schering Corporation Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
US20060046956A1 (en) * 2004-08-27 2006-03-02 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008244A2 (en) * 2000-07-21 2002-01-31 Schering Corporation Peptides as ns3-serine protease inhibitors of hepatitis c virus
WO2003062265A2 (en) * 2002-01-18 2003-07-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
WO2003062228A1 (en) * 2002-01-23 2003-07-31 Schering Corporation Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
US20050020689A1 (en) * 2003-06-17 2005-01-27 Schering Corporation Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof
US20050059648A1 (en) * 2003-06-17 2005-03-17 Schering Corporation Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof
US20050085425A1 (en) * 2003-08-26 2005-04-21 Schering Corporation Novel peptidomimetic NS3-serine protease inhibitors of hepatitis C virus
WO2005085275A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis c virus ns3 protease
WO2005085242A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
WO2005085197A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005087725A2 (en) * 2004-02-27 2005-09-22 Schering Corporation Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005087721A2 (en) * 2004-02-27 2005-09-22 Schering Corporation Compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005087731A1 (en) * 2004-02-27 2005-09-22 Schering Corporation Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
US20060046956A1 (en) * 2004-08-27 2006-03-02 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9163061B2 (en) 2007-12-21 2015-10-20 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof

Also Published As

Publication number Publication date
WO2006130607A2 (en) 2006-12-07
EP1898941A2 (en) 2008-03-19
JP2008545748A (en) 2008-12-18
CA2611145A1 (en) 2006-12-07
NZ563369A (en) 2011-03-31
AU2006252623A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
WO2006130607A3 (en) Controlled-release formulation useful for treating disorders associated with hepatitis c virus
ATE458735T1 (en) PYRIDINO[1,2-A PYRIMIDINE-4-ONE COMPOUNDS AS ANTI-CANCER AGENT
GB0215844D0 (en) Organic compounds
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
WO2010030538A3 (en) Compounds for the treatment of hepatitis c
IS7857A (en) Installs pyrrolo-pyrazole derivatives that inhibit kinase
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
WO2007015824A3 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
WO2007081974A3 (en) Viral hepatitis treatment
WO2006130687A3 (en) Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor
DK1689724T3 (en) Quinazolinone compounds as anticancer agents
WO2007101864A3 (en) Compounds that modulate ppar activity, their preparation and use
WO2007047146A3 (en) Inhibitors of viral replication
MX2012004032A (en) Compounds for the treatment of hepatitis c.
WO2008147557A3 (en) Heteroaryl substituted thiazoles and their use as antiviral agents
WO2008079159A3 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
CL2009000512A1 (en) Substituted heterocyclic compounds derived from imidazo [4,5-d] pyridazine, imidazo [4,5-c] pyridazine, imidazo [4,5d] pyrimidine, among others; pharmaceutical composition comprising said compounds; and use to treat the hepatitis c virus.
WO2003063787A3 (en) Non-steroidal analogs of 2-methoxyestradiol
WO2008103847A3 (en) Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
TNSN07165A1 (en) Organic compounds
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
WO2009029384A3 (en) Compounds for the treatment of hepatitis c
IL191758A0 (en) Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof
WO2006119389A3 (en) Quinine-containing controlled-release formulations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 563369

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2611145

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008514780

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006252623

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006760559

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006252623

Country of ref document: AU

Date of ref document: 20060531

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06760559

Country of ref document: EP

Kind code of ref document: A2